Scharlab Presents th...
LGC Strengthens Posi...
3rd December 2018 Content supplied by: Agilent Technologies, Inc.
Agilent Expands Cell Analysis R&D Capabilities in Ireland
Agilent entered the cell analysis market in 2015 with the acquisition of Seahorse Bioscience, a leader in the development of specialized instruments and live-cell, kinetic assays. The addition of Luxcel expands Agilent's cell analysis portfolio and brings new capabilities through technology and research which will drive advancements in this fast-evolving field for Agilent globally.
"Technological progression allowing researchers to examine cell health and function kinetically, and in real-time, are driving global demand for complete cell analysis solutions," said Todd Christian, general manager, Agilent Cell Analysis Division. “The Luxcel acquisition and Agilent Ireland expansion underscore Agilent’s continued commitment to the growing cell analysis market.”
“We’re excited that Agilent has invested in Ireland,” said Martin Shanahan, chief executive officer, IDA Ireland. “Luxcel has partnerships and active research programs in Ireland, and with major EU and UK research institutions. This expansion will not only provide the most up-to-date and advanced solutions for Agilent’s customers but will have a significant positive impact within the Irish and European innovation ecosystem.”
Date Published: 3rd December 2018
Source article link: View
Scharlab Presents the Scharlau Brand
LGC Strengthens Position in Clinical